What is it about?
This meta-analysis showed that low dose rt-PA was superior to standard dose rt-PA in preventingmajor bleeding events and remained similar efficacy. In addition, compared with heparin, low dose rt-PA didn’t increase the risk of bleeding for eligible PE patients.
Featured Image
Why is it important?
Although the indications of thrombolytic therapy for acute PE are controversial. Thrombolysis may be considered for these patients after they are judged to have clinical evidence of adverse prognosis and low risk of bleeding complications. In terms of reduction of bleeding events and balance between the benefit and risk ratio, lower doses of rt-PA could be considered for PE patients.
Read the Original
This page is a summary of: Lower dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: A systematic review and meta-analysis, Thrombosis Research, March 2014, Elsevier,
DOI: 10.1016/j.thromres.2013.12.026.
You can read the full text:
Resources
Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial.
Optimal dosing of the recombinant tissue-type plasminogen activator (rt-PA) is important in treating pulmonary thromboembolism (PTE). The aim of this study was to compare the efficacy and safety of a 50 mg/2 h rt-PA regimen with a 100 mg/2 h rt-PA regimen in patients with acute PTE. A prospective, randomized, multicenter trial was conducted.Compared with the 100 mg/2 h regimen, the 50 mg/2 h rt-PA regimen exhibits similar efficacy and perhaps better safety in patients with acute PTE.
Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial.
Optimal dosing of the recombinant tissue-type plasminogen activator (rt-PA) is important in treating pulmonary thromboembolism (PTE). The aim of this study was to compare the efficacy and safety of a 50 mg/2 h rt-PA regimen with a 100 mg/2 h rt-PA regimen in patients with acute PTE. A prospective, randomized, multicenter trial was conducted.Compared with the 100 mg/2 h regimen, the 50 mg/2 h rt-PA regimen exhibits similar efficacy and perhaps better safety in patients with acute PTE.
Contributors
The following have contributed to this page